Diagnosis and classifi cation of pulmonary hypertension;Diagnostic et classifi cation de l'hypertension pulmonaire

Presse Medicale

Volumn 39, Issue SUPPL. 1, 2010, Pages

  Montani, David ^a,b,c   Chaouat, Ari ^d,e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; DEXFENFLURAMINE; FENFLURAMINE; PHENYLPROPANOLAMINE; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; CONGENITAL HEART DISEASE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FAMILIAL DISEASE; GENE MUTATION; HEMOLYTIC ANEMIA; HUMAN; HYPOXEMIA; IDIOPATHIC DISEASE; IMMUNE DEFICIENCY; INHERITANCE; LUNG EMBOLISM; METABOLIC DISORDER; PORTAL HYPERTENSION; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SCHISTOSOMIASIS; SYSTEMIC DISEASE; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE; VIRUS INFECTION; CLASSIFICATION; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; HEART CATHETERIZATION; HEART DISEASE; HEMANGIOMA; HOSPITALIZATION; LUNG TUMOR; LUNG WEDGE PRESSURE; MUTATION; PATHOPHYSIOLOGY;

ACTIVIN RECEPTORS, TYPE II; ANEMIA, HEMOLYTIC; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CAUSALITY; FENFLURAMINE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEART CATHETERIZATION; HEART DISEASES; HEMANGIOMA; HUMANS; HYPERTENSION, PULMONARY; LUNG NEOPLASMS; PULMONARY EMBOLISM; PULMONARY VENO-OCCLUSIVE DISEASE; PULMONARY WEDGE PRESSURE; SCHISTOSOMIASIS; SEROTONIN AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 77955936376     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(10)70002-6     Document Type: Article

References (142)

1. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiéry J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT).
2. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiéry J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537. Authors/Task Force Members.
3. Primary Pulmonary Hypertension 1975, World Health organization, Report on a WHO Meeting Geneva. S. Hatano, T. Strasser (Eds.).
4. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):40S-47S.
5. Kovacs G., Berghold A., Scheidl S., Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009, 34:888-894.
6. Montani D., O'Callaghan D., Jaïs X., Savale L., Natali D., Redzepi A., et al. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Respir Rev 2009, 18:272-290.
7. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
8. Cogan J.D., Pauciulo M.W., Batchman A.P., Prince M.A., Robbins I.M., Hedges L.K., et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:590-598.
9. Aldred M.A., Vijayakrishnan J., James V., Soubrier F., Gomez-Sanchez M.A., Martensson G., et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006, 27:212-213.
10. Sztrymf B., Coulet F., Girerd B., Yaici A., Jaïs X., Sitbon O., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008, 177:1377-1383.
11. Elliott C.G., Glissmeyer E.W., Havlena G.T., Carlquist J., McKinney J.T., Rich S., et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006, 113:2509-2515.
12. Rosenzweig E.B., Morse J.H., Knowles J.A., Chada K.K., Khan A.M., Roberts K.E., et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008, 27:668-674.
13. Girerd B., Montani D., Coulet F., Sztrymf B., Yaici A., Jaïs X., et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181:851-861.
14. Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B., Schwalbe E.C., et al. Muta tions of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27:121-132.
15. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000, 37:741-745.
16. Chaouat A., Coulet F., Favre C., Simmoneau G., Weitzenblum E., Soubrier F., et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004, 59:446-448.
17. Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C., Winship I., et al. Clinical and molecular genetic features of pulmonary hypertension in hereditary hemorrhagic telangiectasia. N Engl J Med 2001, 345:325-334.
18. McGoon M., Gutterman D., Steen V., Barst R., McCrory D.C., Fortin T.A., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:14S-34S.
19. Simonneau G., Galiè N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.
20. Humbert M., Nunes H., Sitbon O., Parent F., Hervé P., Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001, 22:459-475.
21. Souza R., Humbert M., Sztrymf B., Jaïs X., Yaïci A., Le Pavec J., et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008, 31:343-348. Erratum in: Eur Respir J 2008 Apr;31(4):912.
22. Walker A.M., Langleben D., Korelitz J.J., Rich S., Rubin L.J., Strom B.L., et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006, 152:521-526.
23. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-587.
24. Chin K.M., Channick R.N., Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 2006, 130:1657-1663.
25. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
26. Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-1093.
27. Launay D., Hachulla E., Hatron P.Y., Jaïs X., Simonneau G., Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007, 86:299-315.
28. de Groote P., Gressin V., Hachulla E., Carpentier P., Guillevin L., Kahan A., et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008, 67:31-36.
29. Meune C., Avouac J., Wahbi K., Cabanes L., Wipff J., Mouthon L., et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008, 58:1803-1809.
30. Tanaka E., Harigai M., Tanaka M., Kawaguchi Y., Hara M., Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002, 29:282-287.
31. Asherson R.A., Higenbottam T.W., Dinh Xuan A.T., Khamashta M.A., Hughes G.R. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990, 17:1292-1298.
32. Burdt M.A., Hoffman R.W., Deutscher S.L., Wang G.S., Johnson J.C., Sharp G.C. Longterm outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999, 42:899-909.
33. Jaïs X., Launay D., Yaici A., Le Pavec J., Tchérakian C., Sitbon O., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58:521-531.
34. Bunch T.W., Tancredi R.G., Lie J.T. Pulmonary hypertension in polymyositis. Chest 1981, 79:105-107.
35. Dawson J.K., Goodson N.G., Graham D.R., Lynch M.P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000, 39:1320-1325.
36. Kim K.K., Factor S.M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987, 18:1293-1296.
37. Mehta N.J., Khan I.A., Mehta R.N., Sepkowitz D.A. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000, 118:1133-1141.
38. Opravil M., Pechère M., Speich R., Joller-Jemelka H.I., Jenni R., Russi E.W., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997, 155:990-995.
39. Sitbon O., Lascoux-Combe C., Delfraissy J.F., Yeni P.G., Raffi F., De Zuttere D., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177:108-113.
40. Nunes H., Humbert M., Sitbon O., Morse J.H., Deng Z., Knowles J.A., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003, 167:1433-1439.
41. Sitbon O., Gressin V., Speich R., Macdonald P.S., Opravil M., Cooper D.A., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 170:1212-1217.
42. Degano B., Yaïci A., Le Pavec J., Savale L., Jaïs X., Camara B., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009, 33:92-98.
43. Hervé P., Lebrec D., Brenot F., Simonneau G., Humbert M., Sitbon O., et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998, 11:1153-1166.
44. Rodríquez-Roisin R., Krowka M.J., Hervé P., Fallon M.B. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). J Hepatol 2005, 42:924-927. ERS (European Respiratory Society) Task Force-PHD Scientific Committee.
45. Hadengue A., Benhayoun M.K., Lebrec D., Benhamou J.P. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991, 100:520-528.
46. Krowka M.J., Swanson K.L., Frantz R.P., McGoon M.D., Wiesner R.H. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006, 44:1502-1510.
47. Kawut S.M., Krowka M.J., Trotter J.F., Roberts K.E., Benza R.L., Badesch D.B., et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008, 48:196-203.
48. Le Pavec J., Souza R., Hervé P., Lebrec D., Savale L., Tcherakian C., et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008, 178:637-643.
49. Eisenmenger V. Die angeborene Defekte der Kammersheidewand des Herzen. Z Klin Med 1897, 132:1.
50. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958, 2:701-712.
51. Daliento L., Somerville J., Presbitero P., Menti L., Brach-Prever S., Rizzoli G., et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998, 19:1845-1855.
52. Besterman E. Atrial septal defect with pulmonary hypertension. Br Heart J 1961, 23:587-598.
53. Hoffman J.I., Rudolph A.M. The natural history of ventricular septal defects in infancy. Am J Cardiol 1965, 16:634-653.
54. Shaw A.P., Ghareed A. The pathogenesis of pulmonary schistosomiasis in Egypt with special reference to Ayerza's disease. J Pathol Bacteriol 1938, 46:401-424.
55. Lapa M.S., Ferreira E.V., Jardim C., Martins Bdo C., Arakaki J.S., Souza R. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. Rev Assoc Med Bras 2006, 52:139-143.
56. Chaves E. The pathology of the arterial pulmonary vasculature in Manson's schistosomiasis. Dis Chest 1966, 50:72-77.
57. de Cleva R., Herman P., Pugliese V., Zilberstein B., Saad W.A., Rodrigues J.J., et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. Hepatogastroenterology 2003, 50:2028-2030.
58. Lapa M., Dias B., Jardim C., Fernandes C.J., Dourado P.M., Figueiredo M., Farias A., et al. Cardiopulmonary manifestations of hepa tosplenic schistosomiasis. Circulation 2009, 119:1518-1523.
59. Castro O., Hoque M., Brown B.D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003, 101:1257-1261.
60. Gladwin M.T., Sachdev V., Jison M.L., Shizukuda Y., Plehn J.F., Minter K., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350:886-895.
61. Aessopos A., Stamatelos G., Skoumas V., Vassilopoulos G., Mantzourani M., Loukopoulos D. Pulmonary hypertension and right heart failure in patients with betathalassemia intermedia. Chest 1995, 107:50-53.
62. Smedema J.P., Louw V.J. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J Afr 2007, 18:84-89.
63. Jaïs X., Till S.J., Cynober T., Ioos V., Garcia G., Tchernia G., Dartevelle P., et al. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin 2003, 27:139-147.
64. Stuard I.D., Heusinkveld R.S., Moss A.J. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med 1972, 287:869-870.
65. Parent F., Egels S., Stzrymf B., et al. Haemodynamic characteristics of patients with sickle cell disease and suspected pulmonary hypertension on the basis of a tricuspid regurgitation jet velocity > 2.5 m/s on doppler echocardiography. Eur Respir J 2006, 28:544s. (Abstract).
66. Anthi A., Machado R.F., Jison M.L., Taveira-Dasilva A.M., Rubin L.J., Hunter L., et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007, 175:1272-1279.
67. Haque A.K., Gokhale S., Rampy B.A., Adegboyega P., Duarte A., Saldana M.J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002, 33:1037-1043.
68. Reiter C.D., Wang X., Tanus-Santos J.E., Hogg N., Cannon R.O., Schechter A.N., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:1383-1389.
69. Gladwin M.T., Lancaster J.R., Freeman B.A., Schechter A.N. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003, 9:496-500.
70. Montani D., Achouh L., Dorfmüller P., Le Pavec J., Sztrymf B., Tchérakian C., et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008, 87:220-233.
71. Montani D., Price L.C., Dorfmuller P., Achouh L., Jaïs X., Yaïci A., et al. Pulmonary venoocclusive disease. Eur Respir J 2009, 33:189-200.
72. Montani D., Dorfmuller P., Maitre S., Jaïs X., Sitbon O., Simonneau G., et al. [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. Presse Med 2010, 39:134-143.
73. Montani D., Kemp K., Dorfmuller P., Sitbon O., Simonneau G., Humbert M. Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med 2009, 30:411-420.
74. Montani D., Jaïs X., Sitbon O., Capron F., Simonneau G., Humbert M. [Pulmonary arterial hypertension]. Rev Mal Respir 2005, 22:651-666.
75. Lantuejoul S., Sheppard M.N., Corrin B., Burke M.M., Nicholson A.G. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006, 30:850-857.
76. Dorfmüller P., Humbert M., Perros F., Sanchez O., Simmoneau G., Müller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
77. Dorfmüller P., Montani D., Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2010, 35:6-8.
78. Escamilla R., Hermant C., Berjaud J., Mazerolles C., Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995, 8:1982-1984.
79. Ruchelli E.D., Nojadera G., Rutstein R.M., Rudy B. Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection?. Arch Pathol Lab Med 1994, 118:664-666.
80. Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L., Robbins I.M., et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003, 167:889-894.
81. Resten A., Maitre S., Humbert M., Rabiller A., Sitbon O., Capron F., et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004, 183:65-70.
82. Holcomb B.W., Loyd J.E., Ely E.W., Johnson J., Robbins I.M. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000, 118:1671-1679.
83. Dufour B., Maitre S., Humbert M., Capron F., Simonneau G., Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998, 171:1321-1324.
84. Rabiller A., Jaïs X., Hamid A., Resten A., Parent F., Haque R., et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006, 27:108-113.
85. Montani D., Jaïs X., Dorfmuller P., Simonneau G., Sitbon O., Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009, 34:1204-1206.
86. Montani D., Jaïs X., Price L.C., Achouh L., Degano B., Mercier O., et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009, 34:1348-1356.
87. Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007, 28:233-241.
88. Gabbay E., Yeow W., Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography. Am J Respir Crit Care Med 2007, 175:A713.
89. Abramson S.V., Burke J.F., Kelly J.J., Kitchen J.G., Dougherty M.J., Yih D.F., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992, 116:888-895.
90. Zener J.C., Hancock E.W., Shumway N.E., Harrison D.C. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol 1972, 30:820-826.
91. Braunwald E., Braunwald N.S., Ross J., Morrow A.G. Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 1965, 273:509-514.
92. Delgado J.F., Conde E., Sanchez V., López-Ríos F., Gómez-Sánchez M.A., Escribano P., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005, 7:1011-1016.
93. Moraes D.L., Colucci W.S., Givertz M.M. Secon dary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
94. Fraser K.L., Tullis D.E., Sasson Z., Hyland R.H., Thornley K.S., Hanly P.J. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999, 115:1321-1328.
95. Cottin V., Nunes H., Brillet P.Y., Delaval P., Devouassoux G., Tillie-Leblond I., et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26:586-593.
96. Weitzenblum E., Hirth C., Ducolone A., Mirhom R., Rasaholinjanahary J., Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
97. Thabut G., Dauriat G., Stern J.B., Logeart D., Lévy A., Marrash-Chahla R., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127:1531-1536.
98. Chaouat A., Bugnet A.S., Kadaoui N., Schott R., Enache I., Ducoloné A., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
99. Tapson V.F., Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006, 3:564-567.
100. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264.
101. Kim N.H. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006, 3:584-588.
102. Dartevelle P., Fadel E., Mussot S., Chapelier A., Hervé P., de Perrot M., et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004, 23:637-648.
103. Jamieson S.W., Kapelanski D.P., Sakakibara N., Manecke G.R., Thistlethwaite P.A., Kerr K.M., et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003, 76:1457-1462. discussion 62-4.
104. Jaïs X., D'Armini A.M., Jansa P., Torbicki A., Delcroix M., Ghofrani H.A., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52:2127-2134.
105. Suntharalingam J., Treacy C.M., Doughty N.J., Goldsmith K., Soon E., Toshner M.R., et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008, 134:229-236.
106. Rubin L.J., Hoeper M.M., Klepetko W., Galiè N., Lang I.M., Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 2006, 3:601-607.
107. Dingli D., Utz J.P., Krowka M.J., Oberg A.L., Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001, 120:801-808.
108. Guilpain P., Montani D., Damaj G., Achouh L., Lefrère F., Le Pavec J., et al. Pulmonary hyper tension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 2008, 76:295-302.
109. Nand S., Orfei E. Pulmonary hypertension in polycythemia vera. Am J Hematol 1994, 47:242-244.
110. Marvin K.S., Spellberg R.D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 1993, 103:642-644.
111. Handa T., Nagai S., Miki S., Fushimi Y., Ohta K., Mishima M., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006, 129:1246-1252.
112. Gluskowski J., Hawrylkiewicz I., Zych D., Wojtczak A., Zielinski J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984, 46:26-32.
113. Shorr A.F., Helman D.L., Davies D.B., Nathan S.D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005, 25:783-788.
114. Bourbonnais J.M., Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008, 32:296-302.
115. Nunes H., Humbert M., Capron F., Brauner M., Sitbon O., Battesti J.P., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006, 61:68-74.
116. Dauriat G., Mal H., Thabut G., Mornex J.F., Bertocchi M., Tronc F., et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006, 81:746-750.
117. Fartoukh M., Humbert M., Capron F., Maître S., Parent F., Le Gall C., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000, 161:216-223.
118. Taveira-DaSilva A.M., Hathaway O.M., Sachdev V., Shizukuda Y., Birdsall C.W., Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007, 132:1573-1578.
119. Harari S., Simonneau G., De Juli E., Brenot F., Cerrina J., Colombo P., et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997, 16:460-463.
120. Simeoni S., Puccetti A., Chilosi M., Tinazzi E., Prati D., Corrocher R., et al. Type 1 neurofibromatosis complicated by pulmonary artery hypertension: a case report. J Med Invest 2007, 4:354-358.
121. Engel P.J., Baughman R.P., Menon S.G., Kereiakes D.J., Taylor L., Scott M. Pulmonary hypertension in neurofibromatosis. Am J Cardiol 2007, 99:1177-1178.
122. Aoki Y., Kodama M., Mezaki T., Ogawa R., Sato M., Okabe M., et al. von Recklinghausen disease complicated by pulmonary hypertension. Chest 2001, 119:1606-1608.
123. Samuels N., Berkman N., Milgalter E., Bar-Ziv J., Amir G., Kramer M.R. Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Thorax 1999, 54:858-859.
124. Stewart D.R., Cogan J.D., Kramer M.R., Miller W.T., Christiansen L.E., Pauciulo M.W., et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?. Chest 2007, 132:798-808.
125. Launay D., Souza R., Guillevin L., Hachulla E., Pouchot J., Simonneau G., et al. Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:223-228.
126. Hamaoka K., Nakagawa M., Furukawa N., Sawada T. Pulmonary hypertension in type I glycogen storage disease. Pediatr Cardiol 1990, 11:54-56.
127. Inoue S., Nakamura T., Hasegawa K., Tadaoka S., Samukawa M., Nezuo S., et al. [Pulmonary hypertension due to glycogen storage disease type II (Pompe's disease): a case report]. J Cardiol 1989, 19:323-332.
128. Humbert M., Labrune P., Sitbon O., Le Gall C., Callebert J., Hervé P., et al. Pulmonary arterial hypertension and type-I glycogenstorage disease: the serotonin hypothesis. Eur Respir J 2002, 20:59-65.
129. Elstein D., Klutstein M.W., Lahad A., Abrahamov A., Hadas-Halpern I., Zimran A. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998, 351:1544-1546.
130. Lee R., Yousem S. The frequency and type of lung involvement in patients with Gaucher's disease. Lab Invest 1998, 58:54A. (Abstract).
131. Li J.H., Safford R.E., Aduen J.F., Heckman M.G., Crook J.E., Burger C.D. Pulmonary hypertension and thyroid disease. Chest 2007, 132:793-797.
132. Ferris A., Jacobs T., Widlitz A., Barst R.J., Morse J.H. Pulmonary arterial hypertension and thyroid disease. Chest 2001, 119:1980-1981.
133. Mercé J., Ferrás S., Oltra C., Sanz E., Vendrell J., Simón I., et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005, 118:126-131.
134. Chu J.W., Kao P.N., Faul J.L., Doyle R.L. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002, 122:1668-1673.
135. Mayer E., Kriegsmann J., Gaumann A., Kauczor H.U., Dahm M., Hake U., et al. Surgical treatment of pulmonary artery sarcoma. J Thorac Cardiovasc Surg 2001, 121:77-82.
136. Anderson M.B., Kriett J.M., Kapelanski D.P., Tarazi R., Jamieson S.W. Primary pulmonary artery sarcoma: a report of six cases. Ann Thorac Surg 1995, 59:1487-1490.
137. Kim H.K., Choi Y.S., Kim K., Shim Y.M., Sung K., Lee Y.T., et al. Surgical treatment for pulmonary artery sarcoma. Eur J Cardiothorac Surg 2008, 33:712-716.
138. Ishiguro T., Kasahara K., Matsumoto I., Waseda R., Minato H., Kimura H., et al. Primary pulmonary artery sarcoma detected with a pulmonary infarction. Intern Med 2007, 46:601-604.
139. Davis A.M., Pierson R.N., Loyd J.E. Mediastinal fibrosis. Semin Respir Infect 2001, 16:119-130.
140. Loyd J.E., Tillman B.F., Atkinson J.B., Des Prez R.M. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988, 67:295-310.
141. Yigla M., Nakhoul F., Sabag A., Tov N., Gorevich B., Abassi Z., et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003, 123:1577-1582.
142. Nakhoul F., Yigla M., Gilman R., Reisner S.A., Abassi Z. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005, 20:1686-1692.